Nordic Fund X Epsilon’s $846 Million Firm Cash Offer ADVANZ PHARMA Corp. Limited

Ashurst advised Morgan Stanley & Co. International plc, acting as financial adviser to Nordic Fund X Epsilon. Appleby, White & Case LLP and Fasken Martineau DuMoulin LLP acted as counsel to ADVANZ PHARMA. Latham & Watkins and Carey Olsen advised Nordic Capital on the deal.

The transaction involved a $846 million firm cash offer for ADVANZ PHARMA Corp. Limited.

The offer will be made by Cidron Aida Bidco Limited, a wholly-owned subsidiary of Nordic Fund X Epsilon, and values the entire issued and to be issued share capital of ADVANZ PHARMA Corp. Limited at approximately $846 million.

ADVANZ PHARMA Corp. Limited is a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with continued access to high quality, niche established medicines.

The Ashurst team is being led by corporate partner Karen Davies (Picture) assisted by senior associate Harry Thimont and associates Demi Pham and Millie Gibbs.

The global Appleby team was led by Appleby Partner Andrew Weaver and Senior Associate Kevin McQuillan. Senior Associate Daniel Healy and Trainee Angharad Prescott also assisted.

The White & Case team in London which advised ADVANZ PHARMA on the transaction was led by partners Mike Weir and Dominic Ross, with support from associates James Turner, Sonica Tolani and Josephine Levick.

Latham advised Nordic Capital on both the M&A and financing for the deal. Latham’s M&A deal team was led by London corporate partners Robbie McLaren and Douglas Abernethy, with associates Emily Cridland, Chris Ramsey, William Temple-Smith, Róisín Mbonu, and Janine Leeder. Latham’s finance deal team was led by finance partner Sam Hamilton and capital markets partner Scott Colwell, with associates Joseph Kimberling, Patrick Kwak, and Lucy Haworth. Regulatory and compliance advice was provided by a cross-border team led by Washington, D.C. partner Elizabeth Richards and London associate Frances Stocks Allen, with San Francisco counsel Betty Pang, and associates Sara Patel, Julie Choi Shin, and Alyssa Lattner.

The Carey Olsen team was led by corporate partner Guy Coltman, with fellow corporate partner David Taylor, counsel David Allen and associates Stephen Le Cornu and Caitlin Hagart. The finance team was led by finance partners Simon Marks and Kate Andrews, with senior associate Bryony Bird and associate Aldo Plater. The Carey Olsen investment funds team also provided specialist input through partner Daniel O’Connor and senior associate Arindam Madhuryya.

Involved fees earner: Daniel Healy – Appleby; Kevin McQuillan – Appleby; Angharad Prescott – Appleby; Andrew Weaver – Appleby; Karen Davies – Ashurst; Millie Gibbs – Ashurst; Demi Pham – Ashurst; Harry Thimont – Ashurst; David Allen – Carey Olsen; Kate Andrews – Carey Olsen; Bryony Bird – Carey Olsen; Guy Coltman – Carey Olsen; Caitlin Hagart – Carey Olsen; Stephen Le Cornu – Carey Olsen; Arindam Madhuryya – Carey Olsen; Daniel O’Connor – Carey Olsen; Aldo Plater – Carey Olsen; David Taylor – Carey Olsen; Simon Marks – Epstein Rosenblum Maoz; Douglas Abernethy – Latham & Watkins; Julie Choi Shin – Latham & Watkins; Scott Colwell – Latham & Watkins; Emily Cridland – Latham & Watkins; Sam Hamilton – Latham & Watkins; Lucy Haworth – Latham & Watkins; Joseph Kimberling – Latham & Watkins; Patrick Kwak – Latham & Watkins; Janine Leeder – Latham & Watkins; Róisín Mbonu – Latham & Watkins; Robbie McLaren – Latham & Watkins; Betty Pang – Latham & Watkins; Sara Patel – Latham & Watkins; Christopher Ramsey – Latham & Watkins; Elizabeth Richards – Latham & Watkins; Frances Stocks Allen – Latham & Watkins; William Giles Temple-Smith – Latham & Watkins; Josephine Levick – White & Case; Dominic Ross – White & Case; Sonica Tolan – White & Case; James Turner – White & Case; Michael Weir – White & Case;

Law Firms: Appleby; Ashurst; Carey Olsen; Epstein Rosenblum Maoz; Latham & Watkins; White & Case;

Clients: ADVANZ PHARMA Corp.; Morgan Stanley; Nordic Capital Limited;